Journey Strategic Wealth’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Journey Strategic Wealth’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-22,257	Closed	-$855K	–	230
2023 Q2	$855K	Buy	+22,257	New	+$572K	0.04%	63

Journey Strategic Wealth's KDNY Position: Q3 2023 in Review

Journey Strategic Wealth sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 22,257 shares — an estimated $855K sold.

Journey Strategic Wealth first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $855K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Journey Strategic Wealth reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Journey Strategic Wealth sold 22,257 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $855K.
Journey Strategic Wealth first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
Journey Strategic Wealth's Chinook Therapeutics, Inc. Common Stock position peaked at $855K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Journey Strategic Wealth's 13F filing for Q3 2023, filed 8 Nov 2023.